Epimedin C

CAS No. 110642-44-9

Epimedin C( —— )

Catalog No. M17144 CAS No. 110642-44-9

Epimedin C was metabolized via desugarization, dehydrogenation, hydrogenation, dehydroxylation, hydroxylation, demethylation and glucuronidation pathways in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 In Stock
5MG 59 In Stock
10MG 129 In Stock
25MG 274 In Stock
50MG 404 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Epimedin C
  • Note
    Research use only, not for human use.
  • Brief Description
    Epimedin C was metabolized via desugarization, dehydrogenation, hydrogenation, dehydroxylation, hydroxylation, demethylation and glucuronidation pathways in vivo.
  • Description
    Epimedin C was metabolized via desugarization, dehydrogenation, hydrogenation, dehydroxylation, hydroxylation, demethylation and glucuronidation pathways in vivo. It has potential activity against osteoporosis by stimulating osteoblasts.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    TGF-beta/Smad
  • Target
    TGFBR
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    110642-44-9
  • Formula Weight
    822.8
  • Molecular Formula
    C39H50O19
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (303.84 mM)
  • SMILES
    C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]1[C@@H]([C@@H](O)[C@@H](O[C@H]1Oc1c(oc2c(c1=O)c(cc(c2CC=C(C)C)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)c1ccc(cc1)OC)C)O)O)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cui L, et al. Biomed Chromatogr. 2014 Oct;28(10):1306-12.
molnova catalog
related products
  • TASP0382088

    A potent, selective ALK5 inhibitor with IC50 of 4.8 nM.

  • SB-431542

    SB-431542 is a potent, specific TGF-β type I receptor (ALK5) inhibitor with IC50 of 94 nM.

  • Protein Kinase C 19-...

    Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity.